Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

Haematologica

Volumn 96, Issue 10, 2011, Pages 1470-1477

  Barragán, Eva ^a   Montesinos, Pau ^a,b   Camos, Mireia ^c   González, Marcos ^d   Calasanz, Maria J ^e   Román Gómez, José ^f   Gómez Casares, Maria T ^g   Ayala, Rosa ^h   López, Javier ⁱ   Fuster, Óscar ^a   Colomer, Dolors ^c   Chillón, Carmen ^d   Larrayoz, María J ^f   Sánchez Godoy, Pedro ^j   González Campos, José ^k   Manso, Félix ^l   Amador, Maria L ^m   Vellenga, Edo ⁿ   Lowenberg, Bob ^o   Sanz, Miguel A ^a,p  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e Instituto de Investigación Sanitaria de Navarra   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL SEVERO OCHOA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^m HOSPITAL MONTECELO   (Spain)

ⁿ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^o ERASMUS MEDICAL CENTER   (Netherlands)

^p UNIVERSITY OF VALENCIA   (Spain)

more..

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Anthracyclines; FLT3mutations; Prognostic factors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BREAKPOINT CLUSTER REGION 3 PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; CD11B ANTIGEN; CD2 ANTIGEN; CD34 ANTIGEN; HLA DR ANTIGEN; IDARUBICIN; LACTATE DEHYDROGENASE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST COUNT; BLEEDING; BLOOD CLOTTING DISORDER; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG INTERMITTENT THERAPY; FEMALE; FEVER; FMS LIKE TYROSINE KINASE 3 GENE; GENE; GENE MUTATION; HEMATOLOGICAL PARAMETERS; HUMAN; INTERNAL TANDEM DUPLICATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROGRANULAR MORPHOLOGY 3 VARIANT; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PRESCHOOL CHILD; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RELAPSE FREE SURVIVAL; RELAPSE RISK SCORE; SCHOOL CHILD; SCORING SYSTEM; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 80054008816     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.044933     Document Type: Article

References (37)

1. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood. 2005;105(12):4792-4799.
2. Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005;106(1):265-273.
3. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res. 2001;61(19):7233-7239.
4. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. German- Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18): 1909-1918.
5. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11(10):1447-1452.
6. Noguera NI, Breccia M, Divona M, Diverio D, Costa V, De Santis S, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002;16(11):2185-2189.
7. Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19(7):1153-1160.
8. Kuchenbauer F, Schoch C, Kern W, Hiddemann W, Haferlach T, Schnittger S. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol. 2005;130(2):196-202.
9. Au WY, Fung A, Chim CS, Lie AK, Liang R, Ma ES, et al. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol. 2004;125(4):463-469.
10. Shih LY, Kuo MC, Liang DC, Huang CF, Lin TL, Wu JH, et al. Internal tandem duplication and Asp835 mutations of fms-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003; 98(6):1206-1216.
11. Xue MX, Qiu HY, Feng YF, Zhu ZL, Chang WR, Liang JY, et al. Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2008;29(11):757-761.
12. Gale RE, Hills R, Pizzey AR, Kottaridis PD, Swirsky D, Gilkes AF, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106(12):3768-3776.
13. Hasan SK, Sazawal S, Dutta P, Pillai LS, Kumar B, Chaubey R, et al. Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications. Hematology. 2007;12(2):99-101.
14. Yoo SJ, Park CJ, Jang S, Seo EJ, Lee KH, Chi HS. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene. Leuk Lymphoma. 2006;47(9): 1788-1793.
15. Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica 2007;92 (7):994-995.
16. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875-1891.
17. Chillón MC, Santamaría C, García-Sanz R, Balanzategui A, María Eugenia S, Alcoceba M, et al. Long FLT3 internal tandem duplications and reduced PML-RARalpha expression at diagnosis characterize a highrisk subgroup of acute promyelocytic leukemia patients. Haematologica. 2010;95 (5):745-751.
18. Sanz MA, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline- based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa- positive acute promyelocytic leukemia. Blood. 1999;94(9):3015-3021.
19. Sanz MA, Martín G, González M, León A, Rayón C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA Group. Blood. 2004;103(4):1237-1243.
20. Sanz MA, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: longterm outcome of the LPA 99 multicenter study by the PETHEMA group. Blood. 2008;112(8):3130-3134.
21. Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4): 1247-1253.
22. De la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008; 111(7):3395-3402.
23. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplications of the FLT3 gene found in acute myeloid leukemia. Leukemia. 1996; 10(12):1911-1918.
24. Moreno I, Martín G, Bolufer P, Barragán E, Rueda E, Roman J, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukaemia. Haematologica. 2003; 88(1):19-24.
25. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-4335.
26. Cheson BD, Bennett JM, Kopecky K, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
27. Gabert J, Beillard E, Van Der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer Program. Leukemia. 2003;17(12): 2318-2357.
28. Bolufer P, Barragan E, Sanz MA, Martín G, Bornstein R, Colomer D, et al. Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemia. Leukemia. 1998; 12(12):2024-2028.
29. Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009;113(4): 775-783.
30. Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010; 95(3):424-431.
31. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
32. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
33. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59-66.
34. Kainz B, Heintel D, Marculescu R, Schwarzinger I, Sperr W, Le T, et al. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J. 2002; 3(6):283-289.
35. Albano F, Mestice A, Pannunzio A, Lanza F, Martino B, Patore D, et al. The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. Haematologica. 2006;91(3):311-316.
36. Paietta E, Goloubeva O, Neuberg D, Bennett JM, Gallagher R, Racevskis J, et al. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin Cytom. 2004;59(1):1-9.
37. Beitinjaneh A, Jang S, Roukoz H, Majhail NS. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010;24(4):831-836.